A method of treatment of prostatitis

 

(57) Abstract:

The invention relates to medicine, namely to urology, and can be used in the treatment of prostatitis. For this patient spend intravenous drip infusion of drug mixtures containing drugs such as the antibiotic is selected according to the antibiogram of the secret of the prostate gland, as well as contrical, troksevazina, PHIBBS, Dimexidum and dimefest in therapeutic doses. The method allows to arrest the worsening of the disease and prevents its recurrence.

The invention relates to medicine, namely to urology, and can be used in the treatment of prostatitis.

Prostatitis is one of the most frequent diseases in men, it affects 30 to 50% of the male population over the age of 14. Currently, there is a significant increase in the frequency of the disease prostatitis. Over the past 2 years among all males, consulted about urological diseases, prostatitis occurred in 37% of cases.

It is known that the prostate has polietiologic nature, among the many causes of disease is the role of the infection. The main efforts of the majority of urologists are directed to seek the replacement of antibiotics every 7 - 10 days has not lost its clinical significance in the treatment of prostatitis drugs of the penicillin group, levomicetina, tetracycline, but we cannot ignore the negative effects of antibiotics on spermatogenesis. Basic antibiotic treatment does not always produce a positive clinical effect. On this basis requires the search for new effective drugs in the treatment of prostatitis.

There is a method of treatment of chronic prostatitis, rectal ultrasound action, and before him are autoguemotransfuzii, and after a course of ultrasound therapy carried out by rectal injection of therapeutic oil mixture. There is also known a method of parenteral administration of antibiotics and other medicines for the treatment of chronic prostatitis (see, for example, Gaidukov, P. (in Russian). Topical issues of urology, 1988, pages 73 - 75).

However, when this treatment fails quickly to stop aggravation and frequent exacerbations.

The purpose of the invention is the shortening of the edema exacerbation, relapse prevention.

The method is as follows.

The patient spend intravenous drip infusion of medicinal mixture of the following composition:

anti the real single dose of 10000 IU;

the troksevazina-300 - 5 ml;

PHIBBS - 2 ml;

dimexide - 20 ml;

dimefest - 10 ml;

water for injection up to 200 ml.

As inhibitors of proteolysis apply contrical, E-aminocaproic acid, indomethacin.

As immune stimulants used pyrogenes, prodigiozan, tissue preparations, anabolic hormones.

The rate of intravenous infusion of 30 - 40 drops/min for a total solution of 200 ml.

In the pharmaceutical composition additionally introduced dimefest, which contributes to improvement of microcirculation of blood in the prostate by blocking the receptors in the vascular wall.

Example. Patient D., 43, was admitted to the urology clinic for acute parenchymatous prostatitis complaining of feeling hot, pain in the perineum and inguinal areas, difficulty urinating. Palpable prostate correct form, tense and painful, border clear. In the excreta of the prostate gland leukocytes in microscopy cover the entire field of view. Bacteriological examination of excreta of selected E. coli sensitive to gentamicin. The treatment involved daily in the in-300 5 ml, PHIBBS 2 ml, dimexide 20 ml, dimefest 10 ml water for injection or saline to 200 ml.

The first control group consisted of 6 patients whose treatment consisted of daily intravenous infusion of medicinal mixture of the following composition: an antimicrobial agent selected taking into account the sensitivity of microflora secret of the prostate gland, an inhibitor of proteolysis, capillaries protector, immunostimulant, dimexide, water or saline solution. The entire course was held on 15 - 20 of these injections. Another treatment of this group of patients was not conducted.

The second control group consisted of 5 patients who were intravenous drug infusion mixture composition in accordance with the proposed method. Another treatment of these patients has not been conducted.

Clinical supervision for all 11 patients was conducted for two years and was in the control of clinical and laboratory pereoborudovanie. When recurrence of prostatitis was conducted common etiopathogenetic treatment.

New drug dimefest from the group of low-toxic organophosphorus compounds exhibits a high therapeutic activity in the treatment of prostatitis. the deposits are on average 5 days. As a result of treatment with the composition of dimefosfona patients more quickly disappeared pain in the perineum and inguinal areas, frequent urination. Normalized local state prostate cancer, biochemical parameters of urine and blood.

Thus, the proposed method of treatment of prostatitis can shorten the period of treatment to prevent relapse. The proposed medicinal composition with timeposted high efficiency, no side effects, easy to use, useful and not expensive.

A method of treatment of prostatitis, including the introduction of medicines, characterized in that the injected intravenously mixture containing drugs such as the antibiotic is selected according to the antibiogram of the secret of the prostate gland, contrical, troksevazina, PHIBBS, Dimexidum and dimefest.

 

Same patents:
The invention relates to medicine, namely and gynecology, and can be used with chemotherapy ascitic ovarian cancer III-IV stages)
The invention relates to medicine, namely to experimental Oncology, and can be used to reduce toxicity and enhance the antitumor activity of cyclophosphamide
The invention relates to medicine, namely to Oncology, and for the treatment of patients with nodular forms of breast cancer
The invention relates to medicine, namely to traumatology and can be used in the damage of skeletal muscles
The invention relates to medicine, namely to cancer and for the treatment of patients with diffuse forms of breast cancer
The invention relates to medicine, namely to Oncology, and for chemotherapy of disseminated breast cancer

The invention relates to a means for prevention, treatment and elimination of consequences of viral, bacterial, cancer, liver diseases, gastrointestinal tract, urinary system, immune system, wounds, burns, stress, used in medicine and veterinary medicine

FIELD: medicine, ophthalmology.

SUBSTANCE: one should apply an autohemocomponent preparation being supernatant liquid of patient's autoblood at increased serotonin content obtained due to irreversible thrombocytic aggregation due to the impact of 0.5 mg ATP per 1.0 ml plasma followed by a 30-min-long centrifuging at the rate of 1000, 2000 and 3000 rot./min for 20, 7 and 3 min, correspondingly. In case of no exudative phenomena on patient's eye bottom the obtained preparation should introduced at the quantity of 7-10 ml once in 48 h for 1 mo (totally, 15 injections). In case of exudative-hemorrhagic phenomena it should be introduced parabulbarly at the volume of 0.5 ml and parenterally - 7.0-10.0 ml once in 48 h for 1 mo per 15 injections, correspondingly. The preparation enables to improve visual functions due to decreased tissue hypoxia and normalization of microcirculation in visual analyzer.

EFFECT: higher efficiency of therapy.

2 cl, 7 dwg, 2 ex

FIELD: medicine, ophthalmology.

SUBSTANCE: one should apply an autohemocomponent preparation being supernatant liquid of patient's autoblood at increased serotonin content obtained due to irreversible thrombocytic aggregation due to simultaneous impact of 0.5 mg ATP per 1.0 ml plasma followed by a 30-min-long centrifuging at the rate of 1000, 2000 and 3000 rot./min for 20, 7 and 3 min, correspondingly. Preparation should introduced parabulbarly at the volume of 0.5-1.0 ml, parenterally - 7.0-10.0 ml once daily at 20 injections for 1 mo. The method enables to increase visual functions due to normalization of functional activity of photoreceptors and neurons of internal layer in retinal peripheral departments.

EFFECT: higher efficiency of therapy.

1 cl, 2 ex

FIELD: coordination compounds synthesis.

SUBSTANCE: invention provides complex comprising calcium and [[(4R)-4[bis[carboxy.kappa.O)methyl]amino-.kappa.N]-6,9-bis[carboxy-.kappa.O)methyl]-1-[(4,4-diphenylcyclohexyl)oxy]-1-hydroxy-2-oxa-6,9-diaza-1-phosphaundecane-11-ylic acid-.kappa.N6,.kappa.N9,-kappa.011]-oxydato(6-)]-,6H, (MS-325) or its salt with physiologically acceptable cation in each case containing essentially no Gf-MS-325. Also described are pharmaceutical agent based on compounds according to claim 1 and a method for preparing galena composition, complex or its salt with physiologically acceptable cation according to claim 1 intended for preparation of pharmaceutical agent reducing effect produced by heavy metals as well as complex or its salt with physiologically acceptable cation according to claim 1 intended for preparation of pharmaceutical agent suitable for NMR diagnostics and/or diagnostic radiology, a method for amplifying patient's image in NMR tomography based on compounds according to claim 1 and above defined complex or its salt with physiologically acceptable cation in each case containing essentially no visualizing metal chelates and MS-325.

EFFECT: increased assortment of complexes with useful medicine-destination properties.

14 cl, 4 dwg, 30 ex

FIELD: experimental medicine.

SUBSTANCE: on should introduce solution into fracture area at the following ratio of ingredients, g/l: 1-hydroxyethylidenediphosphonic acid 1.80 - 2.06, water-free calcium chloride 1.44 - 2.22, gadolinium (III) nitrate hexahydrate 0.30 - 0.40, dysprosium (III) chloride hexahydrate 0.038 - 0.076, moreover, solution's pH corresponds to 7.3 - 7.8. The present innovation enables to shorten the process of bony tissue regeneration in the site of its lesion or defect and, also, shorten the period for restoring normal physiological function of traumatized bone.

EFFECT: higher efficiency of regeneration.

22 ex, 1 tbl

FIELD: experimental medicine.

SUBSTANCE: on should introduce solution into fracture area at the following ratio of ingredients, g/l: 1-hydroxyethylidenediphosphonic acid 1.80 - 2.06, water-free calcium chloride 1.44 - 2.22, gadolinium (III) nitrate hexahydrate 0.30 - 0.40, dysprosium (III) chloride hexahydrate 0.038 - 0.076, moreover, solution's pH corresponds to 7.3 - 7.8. The present innovation enables to shorten the process of bony tissue regeneration in the site of its lesion or defect and, also, shorten the period for restoring normal physiological function of traumatized bone.

EFFECT: higher efficiency of regeneration.

22 ex, 1 tbl

FIELD: medicine.

SUBSTANCE: the present innovation includes polychemotherapy and radiation therapy. Moreover, polychemotherapy should be carried out by the following scheme: on the 1st and the 8th d of the first and the third courses it is necessary to introduce doxorubicin, cyclophosphan, vincristine, and since the 1st to the 14th d - procarbazine and prednisolone; moreover, on the 1st and the 8th d of the second and the fourth courses one should introduce doxorubicin, bleomycin, vinblastine, dacarbazine. The method enables to decrease the quantity of late therapeutic complications, improves the results of relapse-free, total tumor-specific survival rate and decreases the number of polychemotherapeutic cycles.

EFFECT: higher efficiency of therapy.

2 ex

FIELD: veterinary science, chemical-pharmaceutical industry.

SUBSTANCE: invention relates to the development of veterinary agent used for treatment of animals with arachnidism. Agent for treatment of arachnidism comprises 11.6% of Trichlorfon (Dipterex) alcoholic-oily solution and sea-buckthorn oil in the following ratio of component, ml per 100 mk of preparation: 11.6% of Trichlorfon (Dipterex) alcoholic-oily solution, 4.3-25.8, and sea-buckthorn oil, 74.2-95.7. The preparation shows improved permeability and prolonged positive topical effect and its toxicity is lower as compared with the known preparation of the same designation.

EFFECT: improved and valuable veterinary properties of preparation.

FIELD: organophosphorus compounds, medicine.

SUBSTANCE: invention relates to new biologically active phosphonate compounds. Invention describes phosphonate compound of the formula:

wherein R1 and R'1 represent independently hydrogen atom (-H) substituted possibly with -O-(C1-C24)-alkyl, -O-(C1-C24)-alkenyl, -O-(C1-C24)-acyl, -S-(C1-C24)-alkyl, -S-(C1-C24)-alkenyl or -S-(C1-C24)-acyl wherein at least one among R and R'1 doesn't represent -H and wherein indicated alkenyl or acyl comprise from 1 to 6 double bonds; R2 and R'2 represent independently -H substituted possibly with -O-(C1-C7)-alkyl, -O-(C1-C7)-alkenyl, -S-(C1-C7)-alkyl, -S-(C1-C7)-alkenyl, -O-(C1-C7)-acyl, -S-(C1-C7)-acyl, -N-(C1-C7)-acyl, -NH-(C1-C7)-alkyl, -N-((C1-C7)alkyl)2, oxo-group, halogen atom, -NH2, -OH or -SH; R3 represents phosphonate derivative of nucleoside or biphosphonate; X represents compound of the formula:

L represents a valence bond or a bifunctional binding molecule of the formula: -J-(CR2)t-G- wherein t is a whole number from 1 to 24; J and G represent independently -O-, -S-, -C(O)O- or -NH-; R represents -H, unsubstituted or substituted alkyl or alkenyl; m means a whole number from 0 to 6; n = 0 or 1. Also, invention describes pharmaceutical compositions comprising phosphonate compounds, method for treatment of osteoporosis in mammal, method for increasing mineral osseous density, method for prophylaxis of apoptosis of osteoblasts and osteocytes in mammal, method for treatment of viral infection in mammal, method for treatment of growing neoplasm in mammal and method for proliferation of cells. Invention provides preparing new compounds eliciting useful biological properties.

EFFECT: valuable medicinal properties of phosphonate compounds.

17 cl, 2 dwg, 7 tbl, 21 ex

FIELD: chemistry of organophosphorus compounds, medicine, pharmacy.

SUBSTANCE: invention relates to new compounds of the formula (1) showing affinity to one or more GABAB receptors and their pharmaceutically acceptable salts, solvates and stereoisomers but with exception for racemate of (3-amino-2-hydroxypropyl)-phosphinic acid. Invention provides increasing the therapeutic index value.

EFFECT: improved and valuable properties of compounds.

14 cl, 1 tbl, 21 ex

FIELD: medicine.

SUBSTANCE: invention proposes applying bis-phosphonic acids (bis-phosphonates) for the embolic treatment of angiogenesis and corresponding methods for prophylaxis or treatment of angiogenesis by embolization. Invention provides suppression of growth, invasion or metastasis of tumors, treatment of angiogenesis in myocardium ischemia, rheumatic arthritis, osteoarthritis by embolization of newly formed vessels in intra-arterial route of administration of bis-phosphonate (for example, pamidronic acid or zoledronate).

EFFECT: valuable medicinal properties of medicine agents.

10 cl, 3 dwg, 7 ex

Up!